Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples